www.amgenmedinfo.com
866-572-6436
Underlined terms can be clicked for definition.
Tarlatamab is an investigational study drug that is being tested in clinical studies to see if it can help patients with either of two kinds of neuroendocrine cancer: small cell lung cancer (SCLC) or neuroendocrine prostate cancer (NEPC).
Tarlatamab is a type of drug called a bispecific T-cell engager, or BiTE® molecule, that has two key parts: a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells.
Tarlatamab is a type of immunotherapy that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.
Tarlatamab is an investigational study drug that is being used only in clinical studies that are testing its safety and effectiveness in patients with cancer.
DeLLphi-304 is a clinical study comparing tarlatamab with standard of care chemotherapy in patients whose cancer has returned after first-line treatment.
DeLLpro-300 is a clinical study that is testing tarlatamab to see how safe and effective it is at treating patients with neuroendocrine prostate cancer (NEPC) that has spread to another site in the body after one previous treatment.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical study or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.